Article
Similar Survival Outcomes Persist With Intravenous Vs Intraperitoneal Chemo Plus Bevacizumab in Advanced Ovarian Cancer
Rating:
0.0
Views:
76
Likes:
1
Library:
1
No differences in overall and progression-free survival were observed at the GOG-0252 trial update among patients with ovarian cancer who were treated with intravenous or intraperitoneal chemotherapy plus bevacizumab.
Rate This Post
Rate The Educational Value
Rate The Ease of Understanding and Presentation
Interesting or Boring? Rate the Entertainment Value